Business brief
Corporate Shifts in Tech and Pharma
Mobileye searches for new leadership as enterprise software and drug pipelines pivot toward high-margin growth.
Business
Shashua is handing over leadership at an earnings high point — leaving his successor to manage the shift from basic driver-assist features to fully autonomous software.
BackgroundMobileye specializes in advanced driver-assistance systems and went public on the Nasdaq after being spun out of Intel. Shashua co-founded the firm in 1999 and has navigated its complex corporate history, including a massive acquisition and subsequent partial public offering.
- Mobileye reported second-quarter revenue of $508 million, beating consensus analyst estimates of $481.24 million as driver-assistance chip shipments recovered.
- Shashua will remain on the board and has been offered the chairman role, helping to reassure investors of leadership continuity during the search.
- The leadership change coincides with a critical push into next-generation driverless tech, which requires deep automotive partner integrations to scale globally.
Business
ServiceNow's massive bet on Armis is yielding immediate financial returns — proving that enterprise workflows and connected-device security are merging into a single AI-driven software layer.
BackgroundArmis is an Israeli cybersecurity pioneer that specializes in securing connected devices across complex corporate networks. ServiceNow acquired the startup to expand its traditional workflow management software into a unified security and risk control platform.
- Integration of Armis helped ServiceNow expand its security business into a ten-figure segment, broadening its target market among Fortune 500 companies.
- The transaction is projected to contribute roughly 125 basis points to ServiceNow’s full-year subscription revenue growth, validating the high purchase price.
- The acquisition shows how giant enterprise software vendors are increasingly buying Israeli cybersecurity firms to capture larger portions of corporate IT budgets.
Business
Teva is buying its way into specialized pediatric medicine — using high-margin branded drugs to replace lost revenue from its declining generic portfolio.
BackgroundTeva is an Israeli multinational drugmaker that historically dominated the global generic medicine sector. The company is currently executing its "Pivot to Growth" strategy, which prioritizes high-margin branded treatments to offset declining generic revenues.
- The deal structure includes up to $200 million in potential milestone payments, reducing upfront cash outlay while keeping incentives aligned for clinical success.
- Phase 3 trial data indicates ecopipam cuts relapse risk roughly in half for pediatric Tourette patients, clearing a major hurdle toward regulatory approval.
- The treatment is projected to yield high gross margins of 80%, directly supporting Teva's ongoing effort to improve its overall profitability.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.